DDX3 DEAD-box RNA helicase (Hel67) gene disruption impairs infectivity of Leishmania donovani and induces protective immunity against visceral leishmaniasis

[1]  S. Pandey,et al.  In Vitro Antileishmanial Activity of the Essential Oil from Agrimonia pilosa , 2020, National Academy Science Letters.

[2]  Awanish Kumar,et al.  Genetically modified live attenuated vaccine: a potential strategy to combat visceral leishmaniasis. , 2020, Parasite immunology.

[3]  Awanish Kumar,et al.  DNA-based microarray studies in visceral leishmaniasis: identification of biomarkers for diagnostic, prognostic and drug target for treatment. , 2020, Acta tropica.

[4]  Awanish Kumar,et al.  A spotlight on the diagnostic methods of a fatal disease Visceral Leishmaniasis , 2020, Parasite immunology.

[5]  Awanish Kumar,et al.  Identification of trans-2-cis-8-Matricaria-ester from the Essential Oil of Erigeron multiradiatus and Evaluation of Its Antileishmanial Potential by in Vitro and in Silico Approaches , 2019, ACS omega.

[6]  F. Gay,et al.  Leishmaniasis , 2019, The Lancet.

[7]  Awanish Kumar,et al.  Evaluation of antileishmanial potential of computationally screened compounds targeting DEAD-box RNA helicase of Leishmania donovani. , 2019, International journal of biological macromolecules.

[8]  S. Croft,et al.  Leishmaniasis , 2018, The Lancet.

[9]  R. Madhubala,et al.  Genetic manipulation of Leishmania donovani threonyl tRNA synthetase facilitates its exploration as a potential therapeutic target , 2018, PLoS neglected tropical diseases.

[10]  Awanish Kumar,et al.  Slow pace of antileishmanial drug development , 2018 .

[11]  M. Samant,et al.  DDX3 DEAD-box RNA helicase plays a central role in mitochondrial protein quality control in Leishmania , 2016, Cell Death and Disease.

[12]  Uma S. Dubey,et al.  Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs , 2016, Scientific Reports.

[13]  R. Madhubala,et al.  Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis , 2015, Scientific Reports.

[14]  H. Nakhasi,et al.  Targeted Immunology for Prevention and Cure of VL , 2014, Front. Immunol..

[15]  S. Gannavaram,et al.  Deletion of Ubiquitin Fold Modifier Protein Ufm1 Processing Peptidase Ufsp in L. donovani Abolishes Ufm1 Processing and Alters Pathogenesis , 2014, PLoS neglected tropical diseases.

[16]  P. Dagur,et al.  Live Attenuated Leishmania donovani p27 Gene Knockout Parasites Are Nonpathogenic and Elicit Long-Term Protective Immunity in BALB/c Mice , 2013, The Journal of Immunology.

[17]  H. Luján,et al.  In silico analysis of trypanosomatids' helicases. , 2012, FEMS microbiology letters.

[18]  S. Gannavaram,et al.  Deletion of mitochondrial associated ubiquitin fold modifier protein Ufm1 in Leishmania donovani results in loss of β‐oxidation of fatty acids and blocks cell division in the amastigote stage , 2012, Molecular microbiology.

[19]  M. Samant,et al.  Apoptosis-like programmed cell death induces antisense ribosomal RNA (rRNA) fragmentation and rRNA degradation in Leishmania , 2012, Cell Death and Differentiation.

[20]  M. Samant,et al.  Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses. , 2012, The Journal of antimicrobial chemotherapy.

[21]  A. Jardim,et al.  Adenine Aminohydrolase from Leishmania donovani , 2012, The Journal of Biological Chemistry.

[22]  J. M. Requena,et al.  Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation , 2011, Parasites & Vectors.

[23]  B. Ullman,et al.  Generating knock-in parasites: integration of an ornithine decarboxylase transgene into its chromosomal locus in Leishmania donovani. , 2011, Experimental parasitology.

[24]  D. Maslov,et al.  Trypanosome REH1 is an RNA helicase involved with the 3′–5′ polarity of multiple gRNA-guided uridine insertion/deletion RNA editing , 2011, Proceedings of the National Academy of Sciences.

[25]  M. Samant,et al.  Immunization with the DNA-Encoding N-Terminal Domain of Proteophosphoglycan of Leishmania donovani Generates Th1-Type Immunoprotective Response against Experimental Visceral Leishmaniasis1 , 2009, The Journal of Immunology.

[26]  M. Wilson,et al.  Leishmania donovani lacking the Golgi GDP-Man transporter LPG2 exhibit attenuated virulence in mammalian hosts. , 2009, Experimental parasitology.

[27]  N. Ali,et al.  Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. , 2007, Vaccine.

[28]  A. Descoteaux,et al.  Leishmania donovani  lipophosphoglycan blocks NADPH oxidase assembly at the phagosome membrane , 2006, Cellular microbiology.

[29]  B. Ullman,et al.  A Conditional Mutant Deficient in Hypoxanthine-guanine Phosphoribosyltransferase and Xanthine Phosphoribosyltransferase Validates the Purine Salvage Pathway of Leishmania donovani* , 2006, Journal of Biological Chemistry.

[30]  B. Papadopoulou,et al.  Distinct 3′-Untranslated Region Elements Regulate Stage-specific mRNA Accumulation and Translation in Leishmania* , 2005, Journal of Biological Chemistry.

[31]  Syamal Roy,et al.  Kinetoplastid Membrane Protein-11 DNA Vaccination Induces Complete Protection against Both Pentavalent Antimonial-Sensitive and -Resistant Strains of Leishmania donovani That Correlates with Inducible Nitric Oxide Synthase Activity and IL-4 Generation: Evidence for Mixed Th1- and Th2-Like Responses , 2005, The Journal of Immunology.

[32]  H. Nakhasi,et al.  Centrin Gene Disruption Impairs Stage-specific Basal Body Duplication and Cell Cycle Progression in Leishmania* , 2004, Journal of Biological Chemistry.

[33]  K. Anam,et al.  Characterization of Leishmania donovani Antigens Encapsulated in Liposomes That Induce Protective Immunity in BALB/c Mice , 2002, Infection and Immunity.

[34]  S. Bertholet,et al.  Expression of a Mutant Form of Leishmania donovani Centrin Reduces the Growth of the Parasite* , 2001, The Journal of Biological Chemistry.

[35]  B. Herwaldt.  Leishmaniasis , 1999, The Lancet.

[36]  F. Afrin,et al.  Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. , 1997, The Journal of parasitology.

[37]  A. Sher,et al.  Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Nathan,et al.  Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. , 1988, Journal of immunology.